<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54983">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390349</url>
  </required_header>
  <id_info>
    <org_study_id>EP-1001</org_study_id>
    <nct_id>NCT02390349</nct_id>
  </id_info>
  <brief_title>&quot;CuraMed&quot; and &quot;Curamin&quot; in Osteoarthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuroPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuroPharma, Inc.</source>
  <brief_summary>
    <textblock>
      This randomized, placebo-controlled study evaluates the effects of CuraMed ® (BCM-95 ®) and
      Curamin ® in the treatment of osteoarthritis. One group will receive CuraMed, one group will
      receive Curamin and one group will receive placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Curamin and Curamed on joint pain as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Curamin and Curamed on physical performance measures using the Osteoarthritis Research Society International (OARSI) tests of physical function</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>CuraMed (BCM-95)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curamin</intervention_name>
    <arm_group_label>Curamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CuraMed</intervention_name>
    <arm_group_label>CuraMed (BCM-95)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of degenerative hypertrophic osteoarthritis of the knee
             (M17, according to International Classification of Diseases (ICD-10) of bone joints,
             verified by radiography (Grade 1-3 by Kellgren-Lawrence radiographic grades).

        Exclusion Criteria:

          -  subjects with inflammatory and any secondary arthritis

          -  moderate and severe synovitis (grades 2 and 3)

          -  tear of meniscus

          -  chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine
             and nervous systems

          -  allergic anamnesis and drug intolerance

          -  pregnant or nursing

          -  history of substance abuse

          -  subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks
             prior to the study

          -  subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular
             hyaluronate, systemic or intra-articular glucocorticoids within three months prior to
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Narimanyan, PhD MD</last_name>
    <phone>37410 55 04 70</phone>
    <email>natalie.proshyan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armine Haroyan, PhD MD</last_name>
    <phone>37491 42 79 50</phone>
    <email>rheumo_arm@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erebuni Medical Center</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armine Haroyan, PhD MD</last_name>
      <phone>37491427950</phone>
      <email>rheumo_arm@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Armenia</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 8, 2016</lastchanged_date>
  <firstreceived_date>March 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
